Outlook Therapeutics Inc (NASDAQ: OTLK) is 18.52% higher on its value in year-to-date trading and has touched a low of $0.87 and a high of $12.85 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The OTLK stock was last observed hovering at around $2.06 in the last trading session, with the day’s gains setting it 0.18%.
Currently trading at $2.24, the stock is 37.25% and -39.20% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.48 million and changing 8.74% at the moment leaves the stock -65.61% off its SMA200. OTLK registered -73.14% loss for a year compared to 6-month loss of -69.40%. The firm has a 50-day simple moving average (SMA 50) of $3.684 and a 200-day simple moving average (SMA200) of $6.5136.
The stock witnessed a 24.10% gain in the last 1 month and extending the period to 3 months gives it a -57.33%, and is 31.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 17.80% over the week and 13.85% over the month.
Outlook Therapeutics Inc (OTLK) has around 23 employees, a market worth around $60.66M and $0.00M in sales. Fwd P/E is 3.45. Distance from 52-week low is 157.47% and -82.57% from its 52-week high.
The EPS is expected to grow by 42.86% this year.
Outlook Therapeutics Inc (OTLK) Top Institutional Holders
94.0 institutions hold shares in Outlook Therapeutics Inc (OTLK), with institutional investors hold 55.31% of the company’s shares. The shares outstanding are 23.91M, and float is at 16.04M with Short Float at 21.86%. Institutions hold 35.63% of the Float.
The top institutional shareholder in the company is ROSALIND ADVISORS, INC. with over 0.45 million shares valued at $3.32 million. The investor’s holdings represent 3.1534% of the OTLK Shares outstanding.
Outlook Therapeutics Inc (OTLK) Insider Activity
The most recent transaction is an insider purchase by KENYON LAWRENCE A, the company’s Chief Financial Officer. SEC filings show that KENYON LAWRENCE A bought 5,000 shares of the company’s common stock on Sep 26 ’24 at a price of $5.69 per share for a total of $28446.0. Following the purchase, the insider now owns 5946.0 shares.
Outlook Therapeutics Inc disclosed in a document filed with the SEC on Mar 28 ’24 that Haddadin Yezan Munther (Director) bought a total of 1,882 shares of the company’s common stock. The trade occurred on Mar 28 ’24 and was made at $11.82 per share for $22242.0. Following the transaction, the insider now directly holds 5049.0 shares of the OTLK stock.
Still, SEC filings show that on Mar 07 ’24, Evanson Jeff (CHIEF COMMERCIAL OFFICER) acquired 62,484 shares at an average price of $0.42 for $26243.0. The insider now directly holds 808,459 shares of Outlook Therapeutics Inc (OTLK).
